{"title":"Post-vaccination antibodies against SARS-CoV-2: Correspondence.","authors":"Rujittika Mungmunpuntipantip, Viroj Wiwanitkit","doi":"10.12961/aprl.2023.26.01.05","DOIUrl":null,"url":null,"abstract":"<p><p>Dear Editor, we would like to share ideas on the publication \"Post-vaccination antibodies against SARS-CoV-2 in a cohort of workers of a general hospital\"(1). In the cohort and with fresh SARS-CoV-2 infections, Sabater Vidal et al. noticed a general decrease in IgG-S and IgG-NP antibodies following the second dosage of the Pfizer-BioNTech vaccine (1). Additionally, Sabater Vidal et al. advocated booster shots, continuing preventative measures, and further research to determine the vaccine's protection threshold(1). We concur that the COVID-19 can boost resistance in research subjects. Recognizing the impact of earlier asymptomatic COVID-19 is crucial, though. Asymptomatic COVID-19 is not unusual, and anyone can have had it in the past(2). It is important to take into account any potential confounding effects from earlier asymptomatic COVID-19 when interpreting the vaccination's effects.</p>","PeriodicalId":38326,"journal":{"name":"Archivos de prevención de riesgos laborales","volume":"26 1","pages":"49-50"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos de prevención de riesgos laborales","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12961/aprl.2023.26.01.05","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Dear Editor, we would like to share ideas on the publication "Post-vaccination antibodies against SARS-CoV-2 in a cohort of workers of a general hospital"(1). In the cohort and with fresh SARS-CoV-2 infections, Sabater Vidal et al. noticed a general decrease in IgG-S and IgG-NP antibodies following the second dosage of the Pfizer-BioNTech vaccine (1). Additionally, Sabater Vidal et al. advocated booster shots, continuing preventative measures, and further research to determine the vaccine's protection threshold(1). We concur that the COVID-19 can boost resistance in research subjects. Recognizing the impact of earlier asymptomatic COVID-19 is crucial, though. Asymptomatic COVID-19 is not unusual, and anyone can have had it in the past(2). It is important to take into account any potential confounding effects from earlier asymptomatic COVID-19 when interpreting the vaccination's effects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
